Akebia Therapeutics
AKBA
157 hedge funds and large institutions have $394M invested in Akebia Therapeutics in 2025 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 78 increasing their positions, 22 reducing their positions, and 18 closing their positions.
255% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 22
94% more capital invested
Capital invested by funds: $203M → $394M (+$191M)
78% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 18
46% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $1.51M
10% more funds holding
Funds holding: 143 → 157 (+14)
4.67% more ownership
Funds ownership: 36.56% → 41.23% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.36M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$7.94M |
| 3 |
Morgan Stanley
New York
|
+$7.3M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$6.48M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.21M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$5.62M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.08M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.65M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$10 | -5 | Closed |
|
AKBA Hedge Fund Activity: Q2 2025 in Review
157 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2025, worth a combined $394M — up 94% from $203M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AKBA positions and 18 closed out — a net gain of 14 holders — while 78 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $8.36M. The largest seller was Great Point Partners, cutting an estimated $8.21M.
- 157 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2025, up from 143 in Q1 2025.
- Funds reported $394M of Akebia Therapeutics stock for Q2 2025, up 94% quarter-over-quarter.
- 32 funds opened new Akebia Therapeutics positions in Q2 2025 and 18 closed out, a net change of +14 holders.
- The largest Akebia Therapeutics buyer in Q2 2025 was BlackRock, an estimated $8.36M added.
- The largest Akebia Therapeutics seller in Q2 2025 was Great Point Partners, an estimated $8.21M sold.
Based on aggregated 13F filings for Q2 2025.